The role of CT in PET/CT for assessing diffuse infiltration of bone marrow in multiple myeloma using the Durie-Salmon PLUS staging system

被引:5
作者
Wang, Tiantian [1 ,2 ]
Peng, Xin [2 ]
Qiao, Wenli [3 ]
Xing, Yan [3 ]
Yang, Jiqin [4 ]
Zhao, Jinhua [1 ,3 ]
机构
[1] Nanjing Med Univ, Dept Nucl Med, Shanghai Gen Hosp, 100 Haining Rd, Shanghai 200080, Peoples R China
[2] Tengzhou Cent Peoples Hosp, Dept Radiol, Tengzhou 277500, Shandong, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Nucl Med, Sch Med, Shanghai 200080, Peoples R China
[4] Ningxia Med Univ, Dept Nucl Med, Gen Hosp, 804 Shengli St, Yinchuan 750004, Ningxia, Peoples R China
关键词
PET/CT; CT; multiple myeloma; bone marrow diffuse infiltration; focal lesion; false negative; Durie-Salmon PLUS staging system; Revised International Staging System; POSITRON-EMISSION-TOMOGRAPHY; F-18-FDG PET/CT; FDG PET/CT; EXPERIENCE; MANAGEMENT; DIAGNOSIS; FEATURES;
D O I
10.3892/mco.2020.2039
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PET/CT has been identified as one of the routine methods for the assessment of multiple myeloma (MM) bone marrow infiltration. In the routine method of performing PET/CT, the 18F-Fludeoxyglucose (F-18-FDG) uptake in this disease is often used in the assessment of this condition, however CT diagnosis is not currently commonly used. The aim of the present study was to investigate the importance of CT in PET/CT for assessing diffuse infiltration (DI) of bone marrow in MM. MRI was used as a control in the present study, which is the gold standard for assessing DI of bone marrow and is divided into 3 levels: Mild, moderate and severe DI. Subsequently, a total of four combinations of PET and CT results were listed using the enumeration method for the evaluation of DI in the bone marrow. These combinations were respectively compared with the three levels of MR imaging to screen the most consistent method. The concordances of the new method and routine(18)F-FDG PET/CT for the assessment of DI with MR imaging were compared using the McNemar test, respectively. The results of the DI assessment from the two methods were verified by performing Durie-Salmon (D-S) PLUS staging. Compared with MR imaging, the results were as follows: PET and CT exhibited negative results, suggesting mild DI; one of them was positive, suggesting moderate DI; and two were positive, suggesting severe DI. The results of concordance between two methods (new and routine) and MR imaging are indicated as follows: For the new method, McNemar test, P=0.513 and Kappa=0.745; for the routine(18)F-FDG PET/CT method, McNemar test, P=0.03 and Kappa=0.547. Re-performance of D-S PLUS staging presented the following results: New method, McNemar test, P=0.317 and Kappa=0.93; for the routine method, McNemar test, P=0.223 and Kappa=0.811. These findings indicated that the CT component of PET/CT could improve the concordance with MRI results in the assessment of DI, and the same results were obtained when D-S PLUS staging was performed. The CT in PET/CT can enhance diagnostic accuracy in the assessment of DI by reducing the false negatives when compared with the routine(18)F-FDG method.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 23 条
  • [1] F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
    Bartel, Twyla B.
    Haessler, Jeff
    Brown, Tracy L. Y.
    Shaughnessy, John D., Jr.
    van Rhee, Frits
    Anaissie, Elias
    Alpe, Terri
    Angtuaco, Edgardo
    Walker, Ronald
    Epstein, Joshua
    Crowley, John
    Barlogie, Bart
    [J]. BLOOD, 2009, 114 (10) : 2068 - 2076
  • [2] Whole-body MRI versus whole-body MDCT for staging of multiple myeloma
    Baur-Melnyk, Andrea
    Buhmann, Sonja
    Becker, Christoph
    Schoenberg, Stefan Oswald
    Lang, Nicola
    Bartl, Reiner
    Reiser, Maximilian Ferdinand
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2008, 190 (04) : 1097 - 1104
  • [3] Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
    Cavo, Michele
    Terpos, Evangelos
    Nanni, Cristina
    Moreau, Philippe
    Lentzsch, Suzanne
    Zweegman, Sonja
    Hillengass, Jens
    Engelhardt, Monika
    Usmani, Saad Z.
    Vesole, David H.
    San-Miguel, Jesus
    Kumar, Shaji K.
    Richardson, Paul G.
    Mikhael, Joseph R.
    da Costa, Fernando Leal
    Dimopoulos, Meletios-Athanassios
    Zingaretti, Chiara
    Abildgaard, Niels
    Goldschmidt, Hartmut
    Orlowski, Robert Z.
    Chng, Wee Joo
    Einsele, Hermann
    Lonial, Sagar
    Barlogie, Bart
    Anderson, Kenneth C.
    Rajkumar, S. Vincent
    Durie, Brian G. M.
    Zamagni, Elena
    [J]. LANCET ONCOLOGY, 2017, 18 (04) : E206 - E217
  • [4] Guidelines for the use of imaging in the management of patients with myeloma
    Chantry, Andrew
    Kazmi, Majid
    Barrington, Sally
    Goh, Vicky
    Mulholland, Nicola
    Streetly, Matthew
    Lai, Maggie
    Pratt, Guy
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (03) : 380 - 393
  • [5] 18F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders
    Dammacco, Franco
    Rubini, Giuseppe
    Ferrari, Cristina
    Vacca, Angelo
    Racanelli, Vito
    [J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 15 (01) : 1 - 18
  • [6] Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
    Dimopoulos, Meletios
    Kyle, Robert
    Fermand, Jean-Paul
    Rajkumar, S. Vincent
    San Miguel, Jesus
    Chanan-Khan, Asher
    Ludwig, Heinz
    Joshua, Douglas
    Mehta, Jayesh
    Gertz, Morie
    Avet-Loiseau, Herve
    Beksac, Meral
    Anderson, Kenneth C.
    Moreau, Philippe
    Singhal, Seema
    Goldschmidt, Hartmut
    Boccadoro, Mario
    Kumar, Shaji
    Giralt, Sergio
    Munshi, Nikhil C.
    Jagannath, Sundar
    [J]. BLOOD, 2011, 117 (18) : 4701 - 4705
  • [7] DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO
  • [8] 2-U
  • [9] Durie Brian G M, 2003, Hematol J, V4, P379
  • [10] Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance
    Gariani, Joanna
    Westerland, Olwen
    Natas, Sarah
    Verma, Hema
    Cook, Gary
    Goh, Vicky
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 124 : 66 - 72